Has Krish Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $14,184,487 in general payments to Krish Patel, MD across 1,521 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Krish Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Krish Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Krish Patel, MD

Hematology & Oncology · Nashville, TNNPI 1346484821

Payments from drug & device makers

$14,184,487in general payments, 2019–2025

Across 1,521 payments — averaging $9325.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$5.3M
Gilead$1.6M
Janssen Research & Development, LLC$1.4M
Eli Lilly$925K
Genentech, Inc.$628K
F. Hoffmann-la Roche AG$608K
plus $3.7M from 54 others

$8,283in research payments, 2019–2025

Across 10 payments — averaging $828.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

F. Hoffmann-la Roche AG$4K
Pfizer$3K
Bristol Myers Squibb$476

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	114	$5,275,342
Gilead(2 entities)	235	$1,616,177
Janssen Research & Development, LLC	71	$1,445,560
Eli Lilly	26	$925,451
Genentech, Inc.	52	$628,066
F. Hoffmann-la Roche AG	70	$608,090
AbbVie	142	$574,126
Pfizer	30	$541,000
Pharmacyclics LLC, An Abbvie Company	284	$502,141
Trillium Therapeutics USA, LLC	35	$420,893
Bristol Myers Squibb	51	$287,357
Roche Products Limited	23	$280,775
Epizyme, Inc.	2	$250,216
Merck	11	$234,464
Aptevo Therapeutics Inc	14	$146,928
Hoffmann-la Roche Limited	14	$95,579
Astrazeneca UK Limited	15	$71,414
E.r. Squibb & Sons, L.L.C.	39	$64,374
Takeda Pharmaceuticals U.S.A., Inc.	9	$44,666
Lilly USA, LLC	22	$42,182
Genentech USA, Inc.	39	$29,989
ADC Therapeutics America, Inc.	42	$22,677
Beigene USA, Inc.	27	$20,127
Johnson & Johnson	52	$15,409
Adaptive Biotechnologies Corporation	6	$13,802
Seagen Inc.	14	$11,084
Beone Medicines USA, Inc.	7	$3,943
Beigene, Ltd.	2	$3,300
TG Therapeutics, Inc.	2	$2,475
Aurobindo Pharma USA, Inc.	1	$1,950
Incyte Corporation	2	$1,390
Genmab U.S., Inc.	7	$1,109
Morphosys, US Inc.	2	$622
Secura Bio, Inc.	3	$295
Daiichi Sankyo Inc.	7	$182
Janssen Scientific Affairs, LLC	4	$180
Verastem, Inc.	2	$133
Sanofi	2	$118
Bayer	3	$104
Regeneron Healthcare Solutions, Inc.	3	$88
Springworks Therapeutics, Inc.	3	$72
Array Biopharma Inc	3	$59
Novartis	2	$56
Blueprint Medicines Corporation	1	$42
Jazz Pharmaceuticals Inc.	2	$40
GSK	2	$38
Tempus AI, Inc	2	$37
Pharmaessentia USA Corporation	2	$37
Caris MPI, Inc.	2	$34
Coherus Oncology, Inc.	2	$34
Medline Industries LP	2	$28
Deciphera Pharmaceuticals Inc.	1	$28
Legend Biotech USA Inc.	1	$25
EMD Serono, Inc.	1	$25
Stemline Therapeutics Inc.	1	$24
Teleflex LLC	1	$21
Smith+Nephew	1	$20
Exelixis Inc.	1	$19
Accord Healthcare, Inc.	1	$19
Novocure Inc.	1	$16

How this compares

$14,184,487 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.

See all hematology & oncology providers in Tennessee →

Medicare billing

Part B allowed, 2024

$29,475

Medicare patients

122

Services billed

301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Nashville

Erika HamiltonNashville$45.4M
Ian FlinnNashville$41.2M
Johanna BendellNashville$28.5M
Jesus BerdejaNashville$22.2M
Meredith McKeanNashville$16M
Denise YardleyNashville$13.2M
Todd BauerNashville$10.9M
Wade IamsNashville$8.9M
Benjamin GarmezyNashville$8.4M
Brian RiniNashville$8.1M

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →